Related references
Note: Only part of the references are listed.Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma
Robert O. Dillman et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Patient-specific dendritic-cell vaccines for metastatic melanoma
Robert O. Dillman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients
LHM Smit et al.
EUROPEAN JOURNAL OF CANCER (2005)
Biomarkers in melanoma: Stage III and IV disease
GP Linette et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2005)
Design of inhibitors for S100B
J Markowitz et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Phase I/II trial of melanoma patient-speciric vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: Planned interim analysis
R Dillman et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma
R Hatpio et al.
CLINICAL BIOCHEMISTRY (2004)
Prognostic value of serum S-100B in malignant melanoma
R Andrés et al.
TUMORI JOURNAL (2004)
Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma
AP Hamberg et al.
MELANOMA RESEARCH (2003)
Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels
T Banfalvi et al.
ONCOLOGY (2003)
Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma
RO Dillman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma
CS Jury et al.
BRITISH JOURNAL OF DERMATOLOGY (2000)
Share Paper
